Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03653403 · ClinicalTrials.gov registry record · Phase 1

Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control Gel

A Phase 1 study, sponsored by Bausch Health Americas.

Completed
Registry status
Phase 1
Development phase
61
Enrollment target

NCT03653403 is a Phase 1 study that has completed, run by Bausch Health Americas. The registered enrollment target is 61 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03653403, a Phase 1 study, has completed, sponsored by Bausch Health Americas.

COMPLETED
Registry status
Phase 1
Development phase
61 participants
Enrollment target

Study Summary

This will be an open-label study designed to assess the safety and plasma PK of topically applied IDP-126 Gel compared to Control Gel.

Interventions

  • DRUG IDP-126 Gel
  • DRUG Control Gel

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2018-08-08
Est. Completion 2019-06-19
Phase Phase 1

Sponsor

Bausch Health Americas

168 total trials

What the Registry Record Tells You About NCT03653403

The ClinicalTrials.gov registry entry for NCT03653403 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which IDP-126 Gel is the first listed.

NCT03653403 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03653403 about?

NCT03653403 is a clinical study titled "Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control Gel". This will be an open-label study designed to assess the safety and plasma PK of topically applied IDP-126 Gel compared to Control Gel.

What is the current status of trial NCT03653403?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2018-08-08. Estimated completion is 2019-06-19.

What interventions are being tested in trial NCT03653403?

The interventions under investigation include: IDP-126 Gel (DRUG), Control Gel (DRUG).

Who is sponsoring clinical trial NCT03653403?

This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.